Operating Expenses
Acquired IPR&D Expense
Pfizer Acquired IPR&D Expense decreased by 35.4% to $137.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1422.2%, from $9.00M to $137.00M. Over 4 years (FY 2021 to FY 2025), Acquired IPR&D Expense shows a downward trend with a -17.4% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2020
Last reportedQ1 2026May 5, 2026
Metric ID:
abbv_acquired_iprd_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $219.00M | $762.00M | $2.47B | $355.00M | $1.00M | $524.00M | $73.00M | $21.00M | $33.00M | $67.00M | $72.00M | $0.00 | $6.00M | $13.00M | $88.00M | $9.00M | $2.00M | $1.39B | $212.00M | $137.00M |
| QoQ Change | — | +247.9% | +224.0% | -85.6% | -99.7% | >999% | -86.1% | -71.2% | +57.1% | +103.0% | +7.5% | -100.0% | — | +116.7% | +576.9% | -89.8% | -77.8% | >999% | -84.7% | -35.4% |
| YoY Change | — | — | — | — | -99.5% | -31.2% | -97.0% | -94.1% | >999% | -87.2% | -1.4% | -100.0% | -81.8% | -80.6% | +22.2% | — | -66.7% | >999% | +140.9% | >999% |
Range$0.00 – $2.47B
CAGR-9.4%
Avg YoY Growth+975.9%
Median YoY Growth-66.7%
Current Streak2 quarters decline
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $7.00M | $13.00M | $88.00M | $9.00M | $2.00M | $40.00M | $62.00M | $137.00M |
| Total | $6.00M | $13.00M | $88.00M | $9.00M | $2.00M | $1.39B | $212.00M | $137.00M |
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Pfizer's acquired ipr&d expense?
- Pfizer (PFE) reported acquired ipr&d expense of $137.00M in Q1 2026.
- How has Pfizer's acquired ipr&d expense changed year-over-year?
- Pfizer's acquired ipr&d expense increased by 1422.2% year-over-year, from $9.00M to $137.00M.
- What is the long-term trend for Pfizer's acquired ipr&d expense?
- Over 4 years (2021 to 2025), Pfizer's acquired ipr&d expense has grown at a -17.4% compound annual growth rate (CAGR), from $3.47B to $1.61B.